Archivi categoria: aderenza_compliance
Why do American dialysis patients, living in the most scientifically advanced and prosperous country in the world, still face a double-digit risk of death?
Geriatr Gerontol Int. 2016 Nov 21. doi: 10.1111/ggi.12938. [Epub ahead of print]
Anziani, l’allarme dei geriatri: 3 mln di ricoveri per terapie non revisionate e aggiustamenti fai-da-te | Sanità24 – Il Sole 24 Ore
Più del 40% degli accessi al Pronto Soccorso dipende da reazioni avverse a terapie prescritte in over 65 che non sono state riviste per modificarle in base alle reali esigenze del paziente: il
In Europa 200mila morti per la mancata aderenza terapeutica. Tutti decessi evitabili, che ci costano tra 80 e 120 mld l’anno –
NOI sappiamo ed abbiamo fatto, altri hanno solo distrutto e si vantano dei risparmi. Solo ignoranti senza storia nè cultura.
Il dato diffuso oggi al I Congresso Europeo sull’Aderenza alla Terapia organizzato da Senior International Health Association. Si tratta di decessi causati da difficoltà ed errori nel seguire correttamente le cure da parte dei pazienti. Presentata la Carta Europea per l’Aderenza alla Terapia
Statin Use for Primary Prevention of Cardiovascular Disease in Adults | Cardiology | JAMA | The JAMA Network
This Recommendation Statement from the US Preventive Services Task Force recommends use of low- to moderate-dose statins for primary prevention in adults aged 40 to 75 years who have 1 or more CVD risk factors and a calculated CVD event risk of 10% or greater (B recommendation).
Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data | The BMJ
Objective To quantify how a period of intense media coverage of controversy over the risk:benefit balance of statins affected their use. Design Interrupted time series analysis of prospectively collected electronic data from primary care. Setting Clinical Practice Research Datalink (CPRD) in the United Kingdom. Participants Patients newly eligible for or currently taking statins for primary and secondary cardiovascular disease prevention in each month in January 2011-March 2015. Main outcome measures Adjusted odds ratios for starting/stopping taking statins after the media coverage (October 2013-March 2014). Results There was no evidence that the period of high media coverage was associated with changes in statin initiation among patients with a high recorded risk score for cardiovascular disease (primary prevention) or a recent cardiovascular event (secondary prevention) (odds ratio 0.99 (95% confidence interval 0.87 to 1.13; P=0.92) and 1.04 (0.92 to 1.18; P=0.54), respectively), though there was a decrease in the overall proportion of patients with a recorded risk score. Patients already taking statins were more likely to stop taking them for both primary and secondary prevention after the high media coverage period (1.11 (1.05 to 1.18; P<0.001) and 1.12 (1.04 to 1.21; P=0.003), respectively). Stratified analyses showed that older patients and those with a longer continuous prescription were more likely to stop taking statins after the media coverage. In post hoc analyses, the increased rates of cessation were no longer observed after six months. Conclusions A period of intense public discussion over the risks:benefit balance of statins, covered widely in the media, was followed by a transient rise in the proportion of people who stopped taking statins. This research highlights the potential for widely covered health stories in the lay media to impact on healthcare related behaviour.